Holen Sie sich die Stockscreener-App
23.94
3.91%
0.90
Handel nachbörslich:
23.94
Schlusskurs vom Vortag:
$23.04
Offen:
$23.39
24-Stunden-Volumen:
527.21K
Relative Volume:
0.70
Marktkapitalisierung:
$1.44B
Einnahmen:
$439.00K
Nettoeinkommen (Verlust:
$-105.64M
KGV:
-13.30
EPS:
-1.8
Netto-Cashflow:
$-60.70M
1W Leistung:
+3.86%
1M Leistung:
+0.13%
6M Leistung:
-20.17%
1J Leistung:
-46.17%
1-Tages-Spanne:
$22.80
$23.98
1-Wochen-Bereich:
$22.41
$23.98
52-Wochen-Spanne:
$21.97
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
23.94 | 1.37B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Why Janux Therapeutics Inc. is moving todayQuarterly Earnings Summary & Real-Time Volume Analysis - Newser
Predicting Janux Therapeutics Inc. trend using moving averagesWeekly Trade Review & High Conviction Buy Zone Alerts - Newser
Real time breakdown of Janux Therapeutics Inc. stock performanceEarnings Summary Report & Fast Moving Trade Plans - Newser
What momentum shifts mean for Janux Therapeutics Inc.2025 Trading Volume Trends & Fast Moving Trade Plans - Newser
Strategies to average down on Janux Therapeutics Inc.Market Sentiment Review & Entry Point Confirmation Signals - Newser
Key metrics from Janux Therapeutics Inc.’s quarterly dataJuly 2025 Movers & Comprehensive Market Scan Insights - Newser
Multi asset correlation models including Janux Therapeutics Inc.Portfolio Gains Summary & High Accuracy Trade Signal Alerts - Newser
Can momentum traders help lift Janux Therapeutics Inc.July 2025 Market Mood & Precise Entry and Exit Recommendations - Newser
Sentiment analysis tools applied to Janux Therapeutics Inc.July 2025 Chart Watch & Safe Entry Point Identification - Newser
Can Janux Therapeutics Inc. disrupt its industryBond Market & Real-Time Volume Analysis Alerts - khodrobank.com
Custom watchlist performance reports with Janux Therapeutics Inc.Quarterly Earnings Summary & Smart Swing Trading Techniques - Newser
How to recover losses in Janux Therapeutics Inc. stockEarnings Overview Report & Low Drawdown Trading Techniques - Newser
Is Janux Therapeutics Inc.’s ROIC above industry averageMarket Sentiment Summary & Consistent Profit Trading Strategies - khodrobank.com
Risk adjusted return profile for Janux Therapeutics Inc. analyzedJuly 2025 Decliners & Capital Efficient Trade Techniques - Newser
Is Janux Therapeutics Inc. showing signs of accumulationRate Hike & Fast Exit Strategy with Risk Control - Newser
Published on: 2025-09-02 13:17:12 - Newser
Can a trend reversal in Janux Therapeutics Inc. lead to recoveryFed Meeting & Technical Confirmation Alerts - Newser
Janux Therapeutics Inc. stock daily chart insightsWeekly Trend Summary & Fast Entry High Yield Stock Tips - Newser
Published on: 2025-09-02 03:50:49 - Newser
Tick level data insight on Janux Therapeutics Inc. volatility2025 Sector Review & Consistent Profit Trading Strategies - Newser
Can you recover from losses in Janux Therapeutics Inc.2025 Top Gainers & Free Technical Pattern Based Buy Signals - Newser
How to use a screener to detect Janux Therapeutics Inc. breakoutsEarnings Recap Report & Long-Term Safe Investment Ideas - Newser
Is it too late to sell Janux Therapeutics Inc.Treasury Yields & Community Verified Trade Alerts - Newser
Published on: 2025-09-01 15:48:42 - Newser
Werewolf Therapeutics’s SWOT analysis: innovative platform drives stock potential - Investing.com
Why is Janux Therapeutics Inc. stock going downStop Loss & Reliable Volume Spike Alerts - khodrobank.com
Market Recap: Why is Janux Therapeutics Inc. stock going upWeekly Trend Report & Free Long-Term Investment Growth Plans - خودرو بانک
How to integrate Janux Therapeutics Inc. into portfolio analysis toolsEarnings Overview Report & Long-Term Growth Portfolio Plans - Newser
Tools to assess Janux Therapeutics Inc.’s risk profileCPI Data & Weekly Top Performers Watchlists - Newser
Has Janux Therapeutics Inc. formed a bullish divergenceQuarterly Earnings Report & Real-Time Volume Analysis - Newser
Janux Therapeutics Inc. Included in Top Momentum ScanQuarterly Performance Summary & Weekly Setup with High ROI Potential - beatles.ru
Options Data Show Bullish Bias in Janux Therapeutics Inc.Market Activity Report & Weekly Setup with High ROI Potential - beatles.ru
Published on: 2025-08-30 20:43:08 - Newser
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Janux Therapeutics Inc-Aktie (JANX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
May 01 '25 |
Sale |
32.03 |
3,333 |
106,745 |
82,139 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):